Exhibit 99.1

 

 

uniQure Announces 2017 Financial Results and Recent Company Progress

 

~ On Track to Begin Pivotal Study of AMT-061 in Hemophilia B in Q3 2018

 

~ Submitted IND Amendment for AMT-061 Dose Confirmation Study, with Topline Data Expected by End of 2018

 

~ Expects IND Submission for AMT-130 in Huntington’s Disease in the Second Half of 2018

 

~ $159 million of cash and cash equivalents as of December 31, 2017

 

Lexington, MA and Amsterdam, the Netherlands, March 14, 2018 — uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for 2017 and highlighted recent progress across its business.

 

“We ended 2017 with significant momentum across all of our gene therapy programs, and a strong cash position to fund our business into 2020,” stated Matthew Kapusta, chief executive officer of uniQure.  “We remain highly focused on initiating our pivotal study for AMT-061 in hemophilia B and advancing AMT-130 into a Phase I/II study in Huntington’s disease.  We look forward to providing updates on our progress throughout the year, including the presentation of top-line clinical data on AMT-061 by year-end.”

 

Recent Company Progress:

 

·                 Advancing AMT-061 for the treatment of hemophilia B into a pivotal trial

 

·                  In the first quarter of 2018, the Company submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA) supporting its planned AMT-061 dose-confirmation study.  Extensive data including comparability, manufacturing capability and non-clinical safety and bioequivalence were included in the submission.  The Company anticipates initiating the treatment of patients early in the third quarter of 2018 at a single dose of 2 x 10(13) gc/kg. Top line data from these patients are expected to be presented by the end of the year.

 

·                  The process of site selection for the pivotal phase III study has been initiated and reviews by institutional review boards (IRB) are underway. The Company expects to begin patient enrollment in the lead-in phase of the pivotal study in the third quarter of 2018.

 

·                  In the first quarter of 2018, the Company completed the full comparability analysis for AMT-061, which the Company believes continues to support the comparability between AMT-060 and AMT-061.

 

·                  The Company has completed the manufacturing and full quality release of product for use in the dose confirmation study. The product was produced in the Company’s state-of-the-art manufacturing facility in Lexington, Massachusetts.

 

·                  The European Medicines Agency (EMA) issued a positive opinion on Orphan Drug Designation for AMT-061 in hemophilia B.

 

·                 Advancing AMT-130 for the treatment of Huntington’s disease into a Phase I/II study

 

·                  Preclinical data presented at the 13th Annual Huntington’s Disease Therapeutics Conference in Palm Springs, CA demonstrated that knocking down human mutant huntingtin (mHTT) by AMT-130 was safe and well-tolerated in both the deep structure of the striatum and the cortex when

 



 

evaluated in a humanized mouse model of Huntington’s disease. A single administration of AMT-130 resulted in sustained dose-dependent distribution of AAV5, consistent with previous experience, strongly corresponding with human mHTT lowering in this model.  Expression of total mHTT was significantly reduced by up to 87% in the striatum and up to 62% in the cortex at seven months post treatment, resulting in improvements of select behavioral and neuropathological Huntington’s disease phenotypes. Treatment was well tolerated with no adverse events, including no psychiatric or cognitive defects.

 

·                  A GLP-safety and toxicology study in non-human primates is ongoing and expected to conclude mid-year.  Data from this study will be submitted in support of  the IND, which is expected to be submitted to the FDA in the second half of 2018.

 

·                  In January, the Company announced that it had received Orphan Medicinal Product Designation (OMDP) for AMT-130 in Huntingtin’s disease by the EMA. OMPD offers product market exclusivity for ten years in the European Union following regulatory approval, along with tax and financial incentives for companies developing medicines for such orphan indications.

 

·                  Continuing research collaboration with Bristol Myers-Squibb, including AMT-126 for the treatment of congestive heart failure

 

·                  Under the collaboration with Bristol-Myers Squibb, a preclinical study of AMT-126 to assess heart function in a diseased pig model was initiated in January 2018. Pending data from this study, which is expected later this year, the Company and Bristol-Myers Squibb plan to initiate a safety and toxicology study to enable an IND submission.

 

·                 Adding talent to leadership team

 

·                 On March 12, the Company appointed David Cerveny, J.D., as Chief Legal Officer. Prior to joining uniQure, Mr. Cerveny was Chief Legal Officer, General Counsel and Secretary at ConforMIS, Inc., a publicly traded medical technology company. Prior to this, he was Chief Intellectual Property Counsel at Palomar Medical Technologies, Inc., which was subsequently acquired by Cynosure. Earlier in his career, Mr. Cerveny was a partner at Hale & Dorr LLP (now WilmerHale).  Mr. Cerveny earned a Bachelor of Science degree in biomedical engineering from Marquette University and a Juris Doctor degree from Boston College Law School.

 

Upcoming Anticipated Milestones

 

·                  Initiate dosing of patients in the dose confirmation study of AMT-061, data from which will be available by the end of 2018

 

·                  Initiate patient enrollment in the lead-in phase of the pivotal study of AMT-061 in the third quarter of 2018

 

·                  Completion of the GLP-safety and toxicology study of AMT-130 and submission of the IND in Huntington’s disease in the second half of 2018

 

·                  Completion of a preclinical therapeutic heart function study of AMT-126 in congestive heart failure in the second half of 2018

 

·                  Expansion of the Company’s early-stage research pipeline

 

2



 

Financial Highlights

 

Cash Position: As of December 31, 2017, the Company held cash and cash equivalents of $159.4 million, compared to $132.5 million as of December 31, 2016. In October 2017, the Company raised net proceeds of $85.3 million in an underwritten public offering of ordinary shares. The Company currently expects cash and cash equivalents will be sufficient to fund operations into early 2020.

 

Revenues: Revenue for the year ended December 31, 2017 was $13.1 million, compared to $25.1 million for the year ended December 31, 2016. Collaboration revenue for the year ended December 31, 2017 was $9.0 million, compared to $20.2 million for the year ended December 31, 2016. The decrease in collaboration revenue was primarily due to the termination of the Chiesi co-development agreement in July 2017, as well as nonrecurring revenue recognized in the prior year period associated with the production of AMT-126 product supplies.

 

R&D Expenses: Research and development expenses were $72.2 million for the year ended December 31, 2017, compared to $72.5 million for the year ended December 31, 2016. During the year ended December 31, 2017, we recorded expenses related to an increase in the fair market value of the contingent consideration owed to the sellers of the InoCard business, which was offset by cost savings associated with the consolidation of manufacturing activities into our Lexington, Massachusetts facility.

 

SG&A Expenses: Selling, general and administrative expenses were $24.6 million for the year ended December 31, 2017, compared to $26.0 million for the year ended December 31, 2016. The decrease in SG&A expenses was primarily due to certain one-time costs incurred in 2016 related to the settlement of our arbitration proceedings with Extera and the conversion of our financial reporting to U.S. GAAP.  This reduction was offset, in part, by an increase in share-based compensation costs during the year ended December 31, 2017 compared to the prior year.

 

Other income: Other income was $15.4 million for the year ended December 31, 2017, compared to $1.5 million for the year ended December 31, 2016. The current year period includes the full amortization of the outstanding deferred revenue of $13.8 million following the termination of the Company’s collaboration with Chiesi in July 2017.

 

Net Loss: The net loss was $79.3 million, or $2.94 per share, for the year ended December 31, compared to $73.4 million, or $2.93 per share, for the year ended December 31, 2016.

 

About uniQure

 

uniQure is delivering on the promise of gene therapy — single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with liver/metabolic, central nervous system and cardiovascular diseases. www.uniQure.com

 

uniQure Forward-Looking Statements

 

This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to,our upcoming anticipated milestones, the development of our gene therapy product candidates, the transition to our AMT-061 product candidate, the success of our collaborations and the risk of cessation, delay or lack of success of any of our ongoing or planned clinical studies and/or development of our product candidates. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with our and our collaborators’ clinical development activities, collaboration arrangements, corporate reorganizations and strategic shifts, regulatory

 

3



 

oversight, product commercialization and intellectual property claims, as well as the risks, uncertainties and other factors described under the heading “Risk Factors” in uniQure’s Annual Report on Form 10-K filed on March 14, 2018. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future.

 

uniQure Contacts:

 

FOR INVESTORS:

 

FOR MEDIA:

 

 

 

Maria E. Cantor

Eva M. Mulder

Tom Malone

Direct: 339-970-7536

Direct: +31 20 240 6103

Direct: 339-970-7558

Mobile: 617-680-9452

Mobile: +31 6 52 33 15 79

Mobile: 339-223-8541

m.cantor@uniQure.com

e.mulder@uniQure.com

t.malone@uniQure.com

 

4



 

uniQure N.V.

 

UNAUDITED CONSOLIDATED BALANCE SHEETS

 

 

 

December 31,

 

December 31,

 

 

 

2017

 

2016

 

 

 

in thousands, except share and per share amounts

 

Current assets

 

 

 

 

 

Cash and cash equivalents

 

$

159,371

 

$

132,496

 

Accounts receivables and accrued income

 

1,586

 

9,180

 

Prepaid assets and other current assets

 

1,826

 

2,270

 

Total current assets

 

162,783

 

143,946

 

Non-current assets

 

 

 

 

 

Property, plant and equipment, net

 

34,281

 

35,702

 

Intangible assets and goodwill

 

10,100

 

8,789

 

Other non-current assets

 

2,480

 

1,828

 

Total non-current assets 

 

46,861

 

46,319

 

Total assets

 

$

209,644

 

$

190,265

 

Current liabilities

 

 

 

 

 

Accounts payable

 

$

2,908

 

$

5,524

 

Accrued expenses and other current liabilities

 

8,838

 

9,766

 

Current portion of long-term debt

 

1,050

 

605

 

Current portion of deferred rent

 

737

 

684

 

Current portion of deferred revenue

 

4,613

 

6,142

 

Current portion of contingent consideration

 

1,084

 

 

Total current liabilities

 

19,230

 

22,721

 

Non-current liabilities

 

 

 

 

 

Long-term debt, net of current portion

 

19,741

 

19,631

 

Deferred rent, net of current portion

 

9,114

 

6,781

 

Deferred revenue, net of current portion

 

67,408

 

75,612

 

Contingent consideration, net of current portion

 

2,880

 

1,838

 

Derivative financial instruments related party

 

1,298

 

51

 

Other non-current liabilities

 

614

 

 

Total non-current liabilities

 

101,055

 

103,913

 

Total liabilities

 

120,285

 

126,634

 

Total shareholders’ equity

 

89,359

 

63,631

 

Total liabilities and shareholders’ equity

 

$

209,644

 

$

 190,265

 

 

5



 

uniQure N.V.

 

UNAUDITED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

Years ended December 31, 

 

 

 

2017

 

2016

 

2015

 

 

 

in thousands, except share and per share amounts

 

Total revenues

 

$

13,107

 

$

25,098

 

$

10,578

 

Operating expenses:

 

 

 

 

 

 

 

Research and development expenses

 

(72,172

)

(72,510

)

(59,125

)

Selling, general and administrative expenses

 

(24,635

)

(25,999

)

(23,383

)

Total operating expenses

 

(96,807

)

(98,509

)

(82,508

)

Other income

 

15,430

 

1,465

 

779

 

Other expense

 

(3,073

)

 

 

Loss from operations

 

(71,343

)

(71,946

)

(71,151

)

Non operating items, net

 

(8,116

)

(283

)

(12,111

)

Loss before income tax expense

 

(79,459

)

(72,229

)

(83,262

)

Income tax benefit / (expense)

 

199

 

(1,145

)

1,179

 

Net loss

 

$

(79,260

)

$

(73,374

)

$

(82,083

)

 

 

 

 

 

 

 

 

Basic and diluted net loss per common share

 

$

(2.94

)

$

(2.93

)

$

(3.72

)

Weighted average shares used in computing basic and diluted net loss per common share

 

26,984,183

 

25,036,465

 

22,082,345

 

 

6


View differences made from one to another to evaluate Uniqure N.V.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Uniqure N.V..

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account